vs
Aclarion, Inc.（ACON）与BillionToOne, Inc.（BLLN）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是Aclarion, Inc.的4520.1倍（$83.5M vs $18.5K）。BillionToOne, Inc.净利率更高（6.8% vs -10223.7%，领先10230.6%）。BillionToOne, Inc.同比增速更快（117.4% vs 80.6%）
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
ACON vs BLLN — 直观对比
营收规模更大
BLLN
是对方的4520.1倍
$18.5K
营收增速更快
BLLN
高出36.8%
80.6%
净利率更高
BLLN
高出10230.6%
-10223.7%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.5K | $83.5M |
| 净利润 | $-1.9M | $5.7M |
| 毛利率 | 9.7% | 69.9% |
| 营业利润率 | -10785.8% | 11.5% |
| 净利率 | -10223.7% | 6.8% |
| 营收同比 | 80.6% | 117.4% |
| 净利润同比 | 5.0% | 138.3% |
| 每股收益（稀释后） | $1.39 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACONBLLN
| Q4 25 | $18.5K | — | ||
| Q3 25 | $18.9K | $83.5M | ||
| Q2 25 | $19.3K | — | ||
| Q1 25 | $19.0K | — | ||
| Q4 24 | $10.2K | — | ||
| Q3 24 | $14.4K | $38.4M | ||
| Q2 24 | $11.0K | — | ||
| Q1 24 | $10.1K | — |
净利润ACONBLLN
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.7M | $5.7M | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-1.4M | $-14.9M | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-2.4M | — |
毛利率ACONBLLN
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | 69.9% | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | 52.6% | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
营业利润率ACONBLLN
| Q4 25 | -10785.8% | — | ||
| Q3 25 | -9666.2% | 11.5% | ||
| Q2 25 | -8988.6% | — | ||
| Q1 25 | -7856.0% | — | ||
| Q4 24 | -17652.7% | — | ||
| Q3 24 | -8995.3% | -32.9% | ||
| Q2 24 | -10350.6% | — | ||
| Q1 24 | -12609.3% | — |
净利率ACONBLLN
| Q4 25 | -10223.7% | — | ||
| Q3 25 | -9008.0% | 6.8% | ||
| Q2 25 | -8285.9% | — | ||
| Q1 25 | -10728.4% | — | ||
| Q4 24 | -19444.6% | — | ||
| Q3 24 | -9482.7% | -38.8% | ||
| Q2 24 | -11285.0% | — | ||
| Q1 24 | -23720.6% | — |
每股收益（稀释后）ACONBLLN
| Q4 25 | $1.39 | — | ||
| Q3 25 | $-2.93 | $0.10 | ||
| Q2 25 | $-2.75 | — | ||
| Q1 25 | $-9.32 | — | ||
| Q4 24 | $-809.36 | — | ||
| Q3 24 | $-1321.49 | $-1.47 | ||
| Q2 24 | $-1362.83 | — | ||
| Q1 24 | $-3985.22 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.0M | $195.2M |
| 总债务越低越好 | — | $55.0M |
| 股东权益账面价值 | $12.8M | $-239.5M |
| 总资产 | $13.7M | $327.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACONBLLN
| Q4 25 | $12.0M | — | ||
| Q3 25 | $11.3M | $195.2M | ||
| Q2 25 | $12.8M | — | ||
| Q1 25 | $14.8M | — | ||
| Q4 24 | $453.7K | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $1.2M | — | ||
| Q1 24 | $2.1M | — |
总债务ACONBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | $55.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ACONBLLN
| Q4 25 | $12.8M | — | ||
| Q3 25 | $12.5M | $-239.5M | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $15.8M | — | ||
| Q4 24 | $970.1K | — | ||
| Q3 24 | $2.5M | $-242.9M | ||
| Q2 24 | $1.6M | — | ||
| Q1 24 | $2.5M | — |
总资产ACONBLLN
| Q4 25 | $13.7M | — | ||
| Q3 25 | $13.2M | $327.5M | ||
| Q2 25 | $14.8M | — | ||
| Q1 25 | $16.5M | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | $3.7M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.6M | $13.8M |
| 自由现金流经营现金流 - 资本支出 | — | $6.5M |
| 自由现金流率自由现金流/营收 | — | 7.7% |
| 资本支出强度资本支出/营收 | — | 8.8% |
| 现金转化率经营现金流/净利润 | — | 2.42× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACONBLLN
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-1.2M | $13.8M | ||
| Q2 25 | $-1.9M | — | ||
| Q1 25 | $-2.5M | — | ||
| Q4 24 | $-922.9K | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | $-2.2M | — |
自由现金流ACONBLLN
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | $6.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率ACONBLLN
| Q4 25 | — | — | ||
| Q3 25 | -6164.6% | 7.7% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ACONBLLN
| Q4 25 | — | — | ||
| Q3 25 | 38.6% | 8.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率ACONBLLN
| Q4 25 | — | — | ||
| Q3 25 | — | 2.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACON
暂无分部数据
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
